Temsirolimus maintenance therapy after successful docetaxel induction is feasible, does not adversely affect quality of life, and delays radiological and/or symptomatic progression by approximately 6 months in men with castration-resistant prostate cancer (CRPC), a recent study published online ahead of print in the journal The Oncologist has shown.1
Because there is no standard therapy available for patients with CRPC who have responded to docetaxel and do not yet have disease progression, researchers sought to evaluate whether temsirolimus, an mTOR inhibitor, could maintain the response to docetaxel without negatively impacting quality of life.
For the single-arm, phase 2 study, researchers enrolled 21 patients with CRPC who underwent successful docetaxel induction for 6 to 10 cycles. Participants then received temsirolimus maintenance 25 mg weekly for 4 weeks per cycle.
Results showed that median time to treatment failure was 24.3 weeks (95% CI, 16.1 – 33.0) after a median of 7 cycles of temsirolimus. Researchers found that 1 patient achieved a partial tumor response and 1 achieved a prostate-specific antigen (PSA) response. Median time to PSA progression was 12.2 weeks (95% CI, 7.8 – 23.9).
RELATED: Statin Therapy May Help Delay Prostate Cancer Progression in Men Receiving ADT
In regard to safety, grade 3 to 4 adverse events were infrequent, and quality of life scores remained stable during treatment.
Temsirolimus is already approved by the U.S. Food and Drug Administration for the treatment of patients with renal cell carcinoma.
- Emmenegger U, Booth CM, Berry S, et al. Temsirolimus maintenance therapy after docetaxel induction in castration-resistant prostate cancer [published online ahead of print on November 5, 2015]. Oncologist. doi: 10.1634/theoncologist.2015-0220.